Vascular Damage Effectively Reversed Using Hypertension Treatment
A hypertension medication called olmesartan medoxomil is effective in reversing the narrowing of the arteries that occurs in patients with high blood pressure, according to a new study.Carlos M. Ferrario, M.D.
Seven Biomarkers That May Help Pinpoint Prostate Cancer Recurrence Identified By UT Southwestern Urologists
A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.In a study published in Clinical Cancer Research, UT Southwestern scientists identified a panel of seven biomarkers that can predict with 86 percent accuracy which prostate cancer patients will experience a recurrence and progression of the disease.
FDA Allows Halcygen's IND Application, Pivotal US-Based Clinical Trials To Proceed - SUBATM-Itraconazole Is An Improved Anti-fungal
HalcyGen Pharmaceuticals Limited (ASX:HGN) has received approval from the US Food and Drug Administration (FDA) to begin pivotal pharmacokinetic* (PK) studies in the United States. These studies are the precursor to SUBATM-Itraconazole product registration.
Peptimmune Initiates Phase Ib Study Of PI-2301 In Multiple Sclerosis Patients And Presentation At BIO 2008
Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS).
Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY TM Eradicates MRSA From Chronic Venous Ulcers
Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced that its key product, MEDIHONEY(TM) Wound & Burn Dressing with Active Leptospermum Honey, has been found in a large randomized controlled clinical trial to significantly reduce the presence of methicillin-resistant Staphylococcus aureus (MRSA) in chronic wounds.
BaroFold Inc. Initiates First Human Studies For Multiple Sclerosis Drug Candidate, BaroFeron trade;
BaroFold Inc. announced that it has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of BaroFeron™
Tranzyme Pharma's Ghrelin Agonist TZP-102 Demonstrates Safety And High Oral Bioavailability In The Successful Completion Of A Phase I Trial
Tranzyme Pharma announced the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development.
Urges Of Pathological Gamblers Curbed By Drug Commonly Used For Alcoholism
A drug commonly used to treat alcohol addiction has a similar effect on pathological gamblers - it curbs the urge to gamble and participate in gambling-related behavior, according to a new research at the University of Minnesota.Seventy-seven people participated in the double-blind, placebo controlled study.
30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Metho
Results of the RADIATE studyTocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy, according to a new study presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
Abatacept And Infliximab Improve Clinical Response Over Time In Methotrexate-Refractory RA Patients
Results from the ATTEST TrialNew data presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.